Alaunos Therapeutics, Inc. (TCRT) Return on equity 2018–2025
Alaunos Therapeutics, Inc. (TCRT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-194.0%FY2025 · since FY2018: -62.1% → -194.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -194.0% | +32.8 pp |
| FY2024 | -226.8% | -152.6 pp |
| FY2023 | -74.2% | +23.7 pp |
| FY2022 | -97.9% | +37.8 pp |
| FY2021 | -135.6% | -71.1 pp |
| FY2020 | -64.5% | — |
| FY2018 | -62.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice